statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Benitec Biopharma Reports Promising Interim Study Results

An update from Benitec Biopharma (BNTC) is now available. Benitec Biopharma Inc. has released promising interim results from its BB-301 Phase 1b/2a...

Buy Rating Affirmed on Benitec Biopharma Following Promising BB-301 Treatment Results

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Benitec Biopharma (BNTC Research Report) today and set a price target of $16.00...

Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Down 68.3% in March

Benitec Biopharma Inc. (NASDAQ:BNTC  Get Free Report) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 5,100 shares, a...

Benitec Biopharma (NASDAQ:BNTC) Price Target Increased to $10.00 by Analysts at JMP Securities

Benitec Biopharma (NASDAQ:BNTC  Free Report) had its price objective hoisted by JMP Securities from $8.00 to $10.00 in a research report report published on Thursday morning, Benzinga reports...

Benitec Biopharma price target raised by $2 at JMP Securities, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit...

Benitec Biopharma Inc. (NASDAQ:BNTC) Sees Significant Drop in Short Interest

Benitec Biopharma Inc. (NASDAQ:BNTC  Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 6,200 shares...

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The firm's proprietary platforms include DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy and Chronic Hepatitis B. The company was founded in 1995 and is headquartered in Hayward, CA.

Volume	13,318.00
52-Wk High	$10.88
52-Wk Low	$1.86

BNTC Benitec Biopharma Inc

About

Feed

News

Sentiment

Fundamentals